IASO Bio's CAR-T Therapy, Equecabtagene Autoleucel, Advances in Hong Kong and Singapore for Multiple Myeloma
ā¢ IASO Bio's Equecabtagene Autoleucel (FUCASO) NDA has been accepted by the Hong Kong Department of Health for relapsed/refractory multiple myeloma.
ā¢ The CAR-T therapy, already approved in China, is the first fully human CAR-T product and has shown remarkable efficacy and safety.
ā¢ Singapore Health Sciences Authority (HSA) has also accepted the NDA for Equecabtagene Autoleucel, marking a key step in IASO Bio's global expansion.
ā¢ IASO Bio plans to implement a 'Manufactured in China, supplied overseas' model upon approval, expanding access to CAR-T therapies.
Ā© Copyright 2025. All Rights Reserved by MedPath